T cells expressing LFA-1, the counter-receptor of ICAM-1, were significantly and selectively enhanced in the SSc-PAH group at baseline, and LFA-1 expression was downregulated by bosentan therapy. Here, ITGAL is linked to pulmonary arterial hypertension.